Status: Recruiting
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Participants needed: 26
Trial details
Phase: Phase 1, Phase 2Age: Up to 30Biological sex: AllType: InterventionalSponsor: Aspa TherapeuticsUpdated: Apr 17, 2026Locations: 4
Eligibility criteria
Maximum age for inclusion is 30 months. [+5]
Tests positive for total anti-AAV9 antibodies determined by enzyme-linked immuno... [+5]